SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is currently trending with immense community excitement following the landmark approval of its Anktiva therapy for lung and bladder cancer in Saudi Arabia, signaling a potential paradigm shift in oncology. This development, amplified by recent executive discussions, has ignited investor focus on the innovative, non-chemotherapy treatment and fuels widespread speculation of a significant market move amidst high short interest and growing calls for faster US regulatory action.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is currently a major talking point ahead of its upcoming earnings report and the ongoing complexities surrounding a potential Warner Bros. Discovery acquisition. Community sentiment is deeply split, with some anticipating a significant rebound from perceived oversold levels, while others caution about lingering valuation concerns and deal-related risks. The recent disclosure of a prominent figure acquiring bonds in both companies further fuels the debate over its short-term trajectory.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is currently trending due to its exceptionally active and dedicated community, which is relentlessly building a permissionless brand with numerous real-world products and initiatives. Community members express strong bullish conviction, emphasizing long-term growth and the project's consistent expansion of its ecosystem across multiple blockchain platforms like ETH, SOL, and BASE.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin (APP) is experiencing significant market volatility, with community discussion centered on recent sharp declines despite a new analyst upgrade to $835. Bulls argue the stock's AI-powered AXON platform and strong fundamentals make current dips a buying opportunity, often attributing the fall to market manipulation or recurring allegations of fraudulent practices. Conversely, bears highlight the stock's valuation and sector-wide weakness, questioning its stability and anticipating further downside.

Avio SpA provides aerospace propulsion systems, engine modules and components. It specializes in equipment, stage assembly, composite containers and structures, SRM thermal protections, structural elements, SRM nozzle, functional tests, cryogenic propulsion, upper-stage storable propulsion, feeding systems, and spacecraft propulsion. The company was founded in 1908 and is headquartered in Colleferro, Italy.

Avio S.p.A - ADR

Avio American Depositary Shares

Avio American Depositary Shares (AVVSY) is trending due to recent significant launch contract wins and its strategic expansion into the U.S. market with a planned manufacturing facility. The community is actively discussing its strong year-over-year growth and robust fundamentals, perceiving it as an undervalued European pure-play space provider compared to its U.S. peers.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as geopolitical tensions escalate, notably with recent US actions in Venezuela and renewed tariff discussions concerning the EU over Greenland. The community is actively debating its potential as a volatility hedge amidst broader market stability concerns, with many anticipating a significant spike despite its inherent decay characteristics.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is a focal point of market discussion, driven by heightened geopolitical interest in Greenland's critical mineral resources amidst ongoing international negotiations and potential tariffs. The community is actively anticipating a forthcoming corporate business update, expecting positive developments regarding the Tanbreez project's progress and its strategic partnerships, which already account for 100% of its rare earth concentrate production.

Oasis is a layer-one blockchain built to support confidential applications at scale. It’s home to Sapphire, the world’s first private EVM network, Oasis Privacy Layer, a cross-chain privacy solution for any EVM dApp, and Runtime Offchain Logic, a framework that brings trustworthy off-chain computing, onchain. Powered by its ROSE token, Oasis leverages a unique layered architecture and native rollup support, making it ideal for use cases in AI, DeFi, DAOs, gaming, and more.

Oasis Network

Oasis Network ($ROSE) is trending amidst community excitement over its strategic pivot and rebranding to 'Rose AI', emphasizing privacy-enabled decentralized applications. This renewed focus is bolstered by developments like the ROFL Mainnet launch and high-profile collaborations with entities such as Google and BMW. Investors are actively discussing ROSE's potential as an undervalued gem, highlighting its foundational role in confidential computing and secure data solutions at the intersection of Web3 and the rapidly expanding AI sector.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing significant upward momentum due to an unprecedented memory chip shortage, fueled by explosive AI demand for high-bandwidth memory (HBM). Recent catalysts, including a major insider stock purchase and the groundbreaking of new manufacturing facilities, reinforce bullish sentiment, with the community actively debating its 'unstoppable momentum' and 'ridiculously cheap' valuation versus concerns about being 'overextended'.

Direxion Shares ETF Trust - Direxion Daily 20+ Year Treasury Bull 3X Shares

Direxion Daily 20+ Year Treasury Bull 3X Shares

TMF is trending as investors intensely debate the Federal Reserve's path for interest rates, with many anticipating upcoming cuts driven by mounting recessionary signals like rising layoffs and a weakening economy. While some community members are aggressively bullish, expecting a significant rally in long-dated Treasuries, an equally vocal contingent sees bonds as an easy short, believing yields will remain elevated or climb further.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is AIM ImmunoTech (AIM) Stock Outpacing Its Medical Peers This Year?

Here is how AIM ImmunoTech Inc. (AIM) and Alzamend Neuro, Inc. (ALZN) have performed compared to their sector so far this year.

EMBC Q4 Preview: Product Momentum and Strategy Gains to Support Growth?

Embecta's Q4 earnings loom as product momentum, global trends and recent strategic gains set the stage for potential top-line support.

Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital

Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 'Lithium in Brain' Study Conducted at Massachusetts General Hospital Alzamend Neuro Announces Completion of...

EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants

Alzamend Neuro completed its first Phase 2 trial for AL001, a novel lithium therapy aiming for better brain delivery and safety, reducing the need for drug monitoring.read more...

Shares of Alzamend Neuro, Inc. (ALZN) soared 82% on Thursday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.alzamend.com/news-events/press-releases/detail/93/alzamend-neuro-announces-dosing-of-first-patient-in-its">announced</a> the dosing of the first patient in its first Phase II clinical study of AL001 in healthy human subjects.AL001 is a novel lithium-delivery system that has the potential to provide the benefits of marketed lithium salts while mitigating currently experienced toxicities associated with lithium.The system is designed to favorably distribute lithium in the brain, resulting in lower exposure of other body organs and an improved safety profile compared to currently marketed lithium salts.The study in healthy human subjects is expected to help the company determine the best path forward in Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder patients by demonstrating AL001’s targeted effectiveness and reduced systemic side effects, the company said.Lithium is known for its efficacy as a first-line therapy for manic episodes and maintenance in bipolar disorder.However, current lithium salts require regular lithium therapeutic drug monitoring of plasma lithium levels and blood chemistry by a clinician to mitigate adverse events that could affect the kidneys and thyroid.Alzamend said that AL001 would potentially eliminate the need for lithium therapeutic drug monitoring. The company’s previous studies in mice have shown that AL001 ensures better brain absorption while maintaining lower levels of lithium in the blood, it addedAlzamend CEO Stephan Jackman said that the company is expected to announce data from the new study before the end of the year.“This advancement stands to potentially enhance the lives of over 43 million Americans suffering from Alzheimer’s, BD, MDD, and PTSD,” he added.On Stocktwits, retail sentiment around Alzamend jumped from ‘neutral’ to ‘extremely bullish’ over the past 24 hours while message volume soared from ‘extremely low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:630/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_29_at_1_18_03_PM_png_9982df14f5.webp" alt="ALZN's Sentiment Meter and Message Volume as of 1:18 p.m. ET on May 29, 2025 | Source: Stocktwits" width="630" height="63"><figcaption>ALZN's Sentiment Meter and Message Volume as of 1:18 p.m. ET on May 29, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/ALZN">ALZN stock</a> is down by about 44% this year and by about 88% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/uber-stock-falls-after-tesla-s-june-12-robotaxi-launch-report/ch0AH7SRbtU">Uber Stock Falls After Tesla’s June 12 Robotaxi Launch Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled

AL001 has the potential to provide the benefits of marketed lithium salts while mitigating currently experienced toxicities associated with lithium.

Equity

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which is in Phase II clinical trial, and delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bipolar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders, and AL002, which completed preclinical stage, and uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Atlanta, GA.

Current Price	$2.35
Prev Close	$2.25
Open	$2.20
Dividend Yield	0.00%
50-Day Moving Average	$2.19
Beta	0.80
Avg. Volume	55,628.86
PE Ratio	-0.43

52-Week High	$11.02
52-Week Low	$1.69
Market Capitalization	$8.93M
EPS (Annual)	-$11.32
Price to Book	2.04
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

ALZN
Alzamend Neuro Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ALZN News

ALZNAlzamend Neuro Inc